Omnicell Com Stock Price, News & Analysis

Omnicell, a leader in medication management, has partnered with Long Island University to open the Center for Innovative Medication Management (CIMM) in Brooklyn, New York. This state-of-the-art facility aims to enhance pharmacy education through advanced technology and analytics. The initiative allows pharmacy students to gain hands-on experience with medication management technologies, including robotics and software aimed at optimizing medication inventory. This strategic collaboration will also train Omnicell's operational teams, reinforcing the company’s commitment to improving pharmaceutical care delivery. The inaugural classes of the CIMM are set to commence in Summer 2023, emphasizing the importance of technology in preparing future pharmacy leaders.

Omnicell, a provider of medication management solutions, will release its first quarter 2023 financial results on May 2, 2023, after market close.

The company will host a conference call at 4:30 p.m. ET that same day to discuss these results. Interested parties can participate via phone or access a link to the live and archived webcast on the company's Investor Relations page.

Since 1992, Omnicell has focused on transforming pharmacy care delivery, aiming to improve outcomes and reduce costs through advanced automation and analytics. Its services support healthcare facilities in managing medications efficiently, enhancing patient safety, and reducing hospital readmissions.

Omnicell reported its fiscal year 2022 results, revealing total GAAP revenues of $1.296 billion, a 14% increase from 2021. However, fourth-quarter GAAP revenues decreased by 4% year-over-year, reflecting ongoing macroeconomic challenges. The company ended the year with over 150 long-term contracts with major U.S. health systems and a backlog of $1.215 billion. Notably, the Chief Financial Officer will step down on July 1, 2023. For 2023, Omnicell projects bookings between $1.000 billion to $1.100 billion and total revenues between $1.150 billion to $1.190 billion.

Omnicell, Inc. (NASDAQ: OMCL) is set to release its financial results for the fourth quarter and full year 2022 on February 28, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results. Interested parties can listen to the call by dialing (888) 440-4318 in the U.S. or (267) 764-0566 internationally. Omnicell, established in 1992, focuses on transforming pharmacy care delivery through automation and technology, ultimately aiming to improve outcomes and lower costs.

Omnicell, a leader in medication management, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. Pacific Time. The presentation will be available via live and archived webcasts on Omnicell's website. Established in 1992, Omnicell focuses on enhancing pharmacy care delivery through automation and technology, aiming to improve patient safety and operational efficiency for healthcare providers. Their innovative solutions help reduce medication errors and hospital readmissions across North America and the UK.

Omnicell is set to showcase its Advanced Services at the ASHP Midyear Clinical Meeting from December 5-8, 2022, in Las Vegas. These services include IV Compounding, Central Pharmacy Dispensing, Inventory Optimization, Retail Pharmacy, and Specialty Pharmacy Services, all aimed at enhancing medication management efficiency and patient safety. The company's strategy focuses on integrating technology to improve clinical outcomes and create economic value for health systems. Omnicell's efforts could potentially lead to improved operational efficiency and reduced medication errors across healthcare settings.

Omnicell, Inc. (Nasdaq:OMCL), a prominent provider of medication management solutions, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 9:00 a.m. ET. The presentation will feature Randall Lipps, Chairman, President, and CEO, alongside CFO Peter Kuipers. Interested parties can access live and archived webcasts on the Omnicell website. Omnicell has been dedicated to improving pharmacy care delivery since 1992, focusing on enhancing patient safety and operational efficiency through innovative technologies.

Omnicell reported third-quarter 2022 revenues of $348 million, reflecting a 17% increase year-over-year, yet faced profit declines. GAAP net income dropped to $17 million ($0.37 per diluted share), down from $29 million ($0.61) in Q3 2021. Non-GAAP net income was $45 million ($1.00 per diluted share), down from $50 million ($1.08). The company lowered its 2022 guidance amid capital budget freezes, expecting total revenues between $1.284 billion to $1.294 billion. Despite near-term challenges, Omnicell remains confident in its long-term strategy.